PT  - JOURNAL ARTICLE
AU  - Chang, Hong
AU  - Schimmer, Aaron D.
TI  - Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy
AID  - 10.1158/1535-7163.MCT-06-0443
DP  - 2007 Jan 01
TA  - Molecular Cancer Therapeutics
PG  - 24--30
VI  - 6
IP  - 1
4099  - http://mct.aacrjournals.org/content/6/1/24.short
4100  - http://mct.aacrjournals.org/content/6/1/24.full
SO  - Mol Cancer Ther2007 Jan 01; 6
AB  - Livin, also called melanoma inhibitor of apoptosis protein (IAP) or kidney IAP, is a member of the IAP family of caspase inhibitors that selectively binds the endogenous IAP antagonist SMAC and caspase-3, caspase-7, and caspase-9. As such, Livin inhibits apoptosis, and its overexpression renders malignant cells resistant to chemotherapy. Therefore, inhibitors of Livin could be useful adjuncts to chemotherapy in the treatment of malignancies. This review will discuss Livin as a potential therapeutic target and strategies for its inhibition, including antisense oligonucleotides, small-molecule inhibitors, and immune-mediated approaches. [Mol Cancer Ther 2007;6(1):24–30]